Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Martha Wadleigh Martin S. Tallman Elisabeth Paietta Frederick R. Appelbaum Peter D. Emanuel Brian Druker Richard A. Larson Suzanne Kamel-Reid |
| Publication date | November 4, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |